论文部分内容阅读
目的观察和分析α-干扰素治疗慢性丙型肝炎合并糖尿病的效果及安全性。方法 30例慢性丙型肝炎合并糖尿病患者采用α-干扰素和利巴韦林治疗。结果治疗后24例(80.0%)患者血清丙型肝炎病毒(HCV-RNA)转阴,谷丙转氨酶(ALT)由治疗前(156.9±67.8)U/L降至(49.8±18.6)U/L(P<0.05),血糖及其他指标变化不大。结论α-干扰素对丙型肝炎合并糖尿病患者的治疗是安全有效的,值得临床推广应用。
Objective To observe and analyze the efficacy and safety of α-interferon in the treatment of chronic hepatitis C with diabetes mellitus. Methods Thirty patients with chronic hepatitis C and diabetes were treated with a-interferon and ribavirin. Results Serum HCV-RNA was negative in 24 patients (80.0%) after treatment, and the ALT decreased from (156.9 ± 67.8) U / L to (49.8 ± 18.6) U / L (P <0.05), blood glucose and other indicators changed little. Conclusion IFN-α is safe and effective for the treatment of hepatitis C patients with diabetes mellitus, which is worthy of clinical application.